Printer Friendly

Renal dysfunction is a confounder for plasma natriuretic peptides in detecting heart dysfunction in uremic and idiopathic dilated cardiomyopathies.

The cardiac natriuretic peptides of clinical relevance include atrial natriuretic peptide (ANP) 4 B-type natriuretic peptide (BNP), and the N-terminal fragment of proBNP (NT-proBNP). Circulating natriuretic peptide concentrations are greatly increased in patients with either acute or chronic heart failure, acute myocardial infarction, and renal failure (1, 2). Several articles have reported increased peptide concentrations in hemodialysis (HD) patients, possibly due to cardiac dysfunction, fluid overload, and decreased renal clearance of peptides (2, 3). The function and structure of atrial and ventricular chambers in uremic cardiomyopathy are sensitive to volume and pressure overload through a remodeling process characterized by an increase in myocardial fibrosis (4-7). Both myocyte disarray and fibrosis in uremic patients are similar to those observed in patients with idiopathic dilated cardiomyopathy (DCM) (8, 9).

In this study, we compared uremic HD patients with idiopathic DCM patients who showed more severe heart involvement and normal or slightly decreased renal function. We hypothesized that if natriuretic peptide concentrations depended on the severity of heart failure regardless of renal function, higher peptide concentrations should be found in the DCM group; moreover, we hypothesized that DCM patients with lower vs higher glomerular filtration rates (GFRs) have similar peptide concentrations.

Materials and Methods

This cross-sectional observational study enrolled 100 white, adult cardiomyopathy patients, made up of 2 groups of 50 individuals each: a dialysis group with uremic cardiomyopathy (36 men, 14 women) and a nondialysis group with idiopathic DCM (31 men, 19 women).

In accordance with the Declaration of Helsinki, the protocol was approved by the ethics committee of our institution, and written informed consent was obtained from all of the participants. Uremic outpatients undergoing thrice-weekly, standard bicarbonate dialysis with low-flux dialyzers for 6 months or longer, with uremic cardiomyopathy (defined as an abnormality of echocardiographic parameters with systolic or diastolic dysfunction in the absence of other cardiomyopathies) were considered. All patients were anuric. Compensated outpatients with idiopathic DCM with a current left ventricular ejection fraction <50%, an end-diastolic volume index >70 mL/[m.sup.2], and normal or slightly decreased renal function (chronic kidney disease class I-II) made up the control group. The DCM group was divided into 2 subgroups with GFR values below and above the median rates [85 mL * [min.sup.-1] * [(1.73 [m.sup.2]).sup.-1]]. Diagnosis of idiopathic DCM had been previously made according to the current WHO definition (10). Inclusion criteria for both groups were age 25-80 years, body mass index (BMI) 17-35 kg/[m.sup.2], New York Heart Association (NYHA) class I-II, normal body hydration as assessed by the bioelectrical impedance vector analysis (11), and normal cardiac troponin I (<0.15 [micro]g/L, decision level for myocardial damage, with a CV <10%, on RxL Dimension, Dade Behring) (12). Exclusion criteria for both groups were atrial fibrillation, pacemakers, previous surgical heart procedures, valvular and congenital heart disorders, myocardial ischemic events, pericardial effusion, edema, diabetes, pulmonary disorders, liver disorders, alcohol abuse (>90 g/day longer than 5 years), cancer, and treatment with cytotoxic drugs.

Protocol measurements were carried out on the same day and included height, body weight, BMI (weight in kg/squared height in [m.sup.2]), systolic and diastolic blood pressure, mean blood pressure, heart rate, electrocardiogram, echocardio-Doppler, whole body bioelectrical impedance (resistance and reactance components at 50 kHz frequency, BIA-101 analyzer, RJL Systems) (11), and routine clinical laboratory tests (plasma Na, K, Ca, urea, hemoglobin). An alkaline picrate method was used for creatinine measurement (calibration traceable to isotope dilution mass spectrometry, Roche Diagnostics). C-reactive protein (CRP) was measured in lithium-heparin plasma using a high-sensitivity assay (Cardiophase hsCRP), with total CVs ranging from 2.1% to 5.7% at 0.5 to 56.0 mg/L. NT-proBNP was assayed on lithium-heparin plasma (PBNP, Dade Behring), with a total CV of 3.1% to 5.7% at 159 to 3734 ng/L and decision threshold of 125 or 450 ng/L for participants younger than or older than 75 years, respectively. BNP was assayed on plasma K3-EDTA (BNP, Bayer Diagnostics) with total CVs of 2.8% to 5.4% at 42 to 1615 ng/L, and a decision threshold of 100 ng/L. ANP was assayed on plasma [K.sub.3] EDTA (Shionogi) with total CVs of 5.7% to 6.0% at 20 to 563 ng/L without an established decision threshold.

Doppler echocardiography was performed following recommendations of the American Society of Echocardiography (13). Complete M-mode, 2-dimensional, and Doppler echocardiograms were performed with a Hewlett-Packard 5500 Sonos system by use of a 2.5-MHz combined imaging and Doppler transducer. The left ventricular mass was calculated with the Devereux formula (14) and was indexed by body surface area (g/m). An end-diastolic volume index >70 mL/[m.sup.2] was considered a ventricle dilation. A left ventricular ejection fraction <50% was defined as systolic dysfunction. Left ventricular diastolic function was classified into 4 patterns (15,16): normal, E/A >1, DT <220 ms, IRT <100 ms; abnormal relaxation, E/A <1 in individuals <55 years or E/A <0.8 in individuals >55 years, DT >220 ms, IRT >100 ms; pseudonormal: 1 < E/A < 2,150 ms < DT < 200 ms, IRT <100 ms; restrictive filling, E/A >2, DT <150 ms, IRT <60 ms, where E is the peak E-wave velocity and A is the peak A-wave velocity of the mitral inflow, DT is the deceleration time of the E wave, and IRT is the left ventricular isovolumic relaxation time (13). The index of myocardial performance (Tei index) was calculated as the ratio isovolumic contraction time plus isovolumic relaxation time)/ejection time, which reflects the global myocardial performance (reference value <0.4) and combines systolic and diastolic elements (17).

In DCM patients, GFR was estimated according to kidney/Dialysis Outcomes Quality Initiative recommendations using the simplified Modification of Diet in Renal Disease equation (18) not applicable to anuric HD patients. In the dialysis patients, body weight, blood pressure, bioelectrical impedance, routine laboratory tests, and natriuretic peptides were recorded before and after a midweek dialysis session.

Statistical calculations were performed with SPSS statistical software (SPSS, version 14). After the natural logarithmic (Ln) transformation of the natriuretic peptides and CRP values (distributions skewed to the right), we obtained log-normal distributions (Kolmogorov-Smirnov test) that were suitable for parametric statistical tests (1- and 2-way ANOVA and Student t-test). We used the Wilcoxon test to analyze the skewed distributions of differences with negative values (log transformation not allowed). We analyzed frequency distributions using Fisher exact test. The diagnostic performance of natriuretic peptides was evaluated by use of ROC curves. The relationships between natriuretic peptides and protocol variables were evaluated with the simple linear correlation coefficient r (determination coefficient [r.sup.2]) and multiple linear regression analysis (multiple correlation coefficient R, and multiple determination coefficient [R.sup.2]). Manual backward elimination was performed on blocks of variables until regression models with only significant variables were obtained. P <0.05 was considered significant in all the statistical tests.


Demographic and metabolic characteristics of patients (predialysis in HD patients) are shown in Table 1. The DCM group was divided into 2 subgroups with median GFRs of 85-126 mL * [min.sup.-1] * [(1.73 [m.sup.2]).sup.-1] and 52-84 mL * [min.sup.-1] * [(1.73 [m.sup.2]).sup.-1]. Patients in both disease groups and in both GFR subgroups belonged to the same NYHA class (I and II), age, and BMI range, and were free from diabetes and heart ischemic events.

BNP, ANP, and NT-proBNP were highly correlated to one another within groups (0.81 < r < 0.97, P <0.001) and also in the pooled groups (0.86 < r < 0.90, P >0.001). The correlation between Ln NT-proBNP and Ln BNP is depicted in the scattergram in Fig. 1. Mean peptide concentrations were higher in the HD group, with an HD:DCM ratio of 24.7 for NT-proBNP (1584-274 995 ng/L in HD vs 10-9162 ng/L in DCM), 4.7 for BNP (28-7625 ng/L in HD vs 2-1387 ng/L in DCM), and 4.8 for ANP (24-904 ng/L in HD vs 3-413 ng/L in DCM) (Table 1). None of the 50 HD patients and 24% of the 50 DCM patients [17% with GFR >85 mL * [min.sup.-1] * [(1.73 [m.sup.2]).sup.-1]] had normal NT-proBNP concentrations. All the HD patients and 76% of the DCM patients [61% with GFR >85 mL * [min.sup.-1] * [(1.73 [m.sup.2]).sup.-1]] had abnormal NT-proBNP concentrations. Normal BNP concentrations were found in 14% of the HD patients and in 60% of the DCM patients [30% with GFR >85 mL * [min.sup.-1] * [(1.73 [m.sup.2]).sup.-1]]. Abnormal BNP concentrations were found in 86% of the HD patients and 40% of the DCM patients [80% with GFR >85 mL * [min.sup.-1] * [(1.73 [m.sup.2]).sup.-1]]. Mean individual peptide concentrations by sex and NYHA class were comparable within the HD and DCM groups (2-way ANOVA: sex P = 0.55-0.97, NYHA P = 0.29-0.94).


Most echocardiographic findings were significantly different in the disease groups (Table 2). In the HD group, the relative wall thickness and the left atrial volume index were greater than those in the DCM group. The heart was more severely affected in the DCM patients in whom the ejection fraction was decreased (ejection fraction <50% in 100% of DCM vs 10% of HD group), the diastolic volume was increased (dilation in 100% of DCM vs 36% of HD), the index of myocardial performance was worse (0.7 in DCM vs 0.4 in HD), and the left ventricular mass index was increased (172 g/[m.sup.2] in DCM vs 151 g/[m.sup.2] in HD, marginally significant, P = 0.05). The frequency distribution of diastolic patterns was comparable in the disease groups (Fisher exact test) [borderline normal with abnormal relaxation patterns in one category (N-AR) vs pseudonormal with restrictive patterns in another category (Pn-R)]. The 3 natriuretic peptides were significantly increased in patients with a Pn-R vs N-AR pattern in both disease groups, but this difference was obscured by the greater increase in peptide concentrations found in the HD patients compared to the DCM patients with the same diastolic pattern (Fig. 2). For instance, a BNP value of 150 ng/L (5 in the Ln scale in Fig. 2) can be found in an HD patient with a N-AR diastolic pattern as well as in a DCM patient with a Pn-R pattern.

The influence of extreme GFR values on natriuretic peptides was stronger than the degree of heart involvement. As a consequence, we obtained misleading ROC curve patterns of natriuretic peptides in detecting systolic dysfunction (ejection fraction <50%). The areas under the ROC curve for all 100 participants were small, ranging from 0.10 to 0.26 for the 3 peptides. The areas under the ROC curves modestly increased to the values of 0.23 to 0.40 for the 3 peptides in detecting an ejection fraction <40%. In the DCM group, all patients had an ejection fraction <50% by inclusion criteria, whereas 54% had an ejection fraction <40%. The area under the ROC curve increased to 0.64 for NT-proBNP [not significant (NS)], 0.66 for BNP (NS), and 0.70 for ANP (P = 0.02) in detecting an ejection fraction <40%.


In DCM patients, the concentration of the 3 natriuretic peptides linearly increased with decreasing GFR irrespective of the severity of heart involvement [significant inverse correlation, P <0.001, between GFR and Ln NT-proBNP, r = -0.54 (Fig. 3A); Ln BNP, r = -0.50 (Fig. 3B); and Ln ANP, r = -0.49]. As a consequence, mean natriuretic peptide concentrations were higher in patients with GFR below the median [52 to 84 mL * [min.sup.-1] * [(1.73 [m.sup.2]).sup.-1] compared to those above it (85 to mL * [min.sup.-1] * [(1.73 [m.sup.2]).sup.-1]], with a ratio of 4.1 for NT-proBNP, 3.4 for BNP, and 2.4 for ANP, although most echo-Doppler variables were comparable in the 2 GFR groups (Tables 1 and 2).

Natriuretic peptides were linearly correlated with several continuous protocol variables in both groups (0.20 < r < 0.54, P = 0.04 to P <0.001). The highest correlations were found between natriuretic peptides and the left atrial volume index in both disease groups (r = 0.54, P <0.001). Most correlation coefficients were of the same order due to the high mutual correlation between peptides. Multiple regression analysis was used to identify among the correlated variables those with an independent influence on natriuretic peptide concentrations both before and after a dialysis session. The prediction of NT-proBNP concentration achieved the highest R value both before (R = 0.85, P <0.001) and after (R = 0.83, P <0.001) the dialysis session, followed by Ln BNP (R = 0.65 and 0.62, P <0.001) and Ln ANP (R = 0.53 and 0.59, P <0.001). Standardized partial regression coefficients ([beta]) indicated that uremic status was the most important variable, both before and after dialysis, followed in decreasing order by diastolic pattern, atrial volume index, and BMI. The following regression equations significantly fitted natriuretic peptide concentration before dialysis (disease encoded 0 if DCM, 1 if HD; D pattern encoded 0 if N-AR, 1 if Pn-R):

Ln(NT-proBNP) = 7.48 + 3.05 Disease + 1.29 D Pattern + 0.02 Atrial volume - 0.11BMI

Ln(BNP) = 5.94 + 1.42 Disease + 1.37 D Pattern + 0.02 Atrial volume - 0.12 BMI

Ln(ANP) = 4.49 + 1.44 Disease + 0.80 D Pattern + 0.02 Atrial volume - 0.08 BMI.


The diastolic pattern, atrial volume, and BMI significantly fitted the peptide distribution also within each disease group [Ln NT-proBNP, R = 0.60 and 0.62 (P <0.001); Ln BNP, R = 0.65 and 0.62 (P <0.001); Ln ANP, R = 0.53 and 0.59 (P <0.001), in the DCM and HD groups, respectively]. In the DCM group, GFR did not significantly correlate with left ventricular mass and volumes (-0.31 < r < -0.20). Although mean values of left ventricular mass and diastolic and systolic volumes were significantly increased in the lower GFR group (P = 0.03, Table 2), GFR was the only significant explanatory variable for natriuretic peptides in a multiple regression equation that included GFR and left ventricular mass and volumes (0.52 < R <0.57, P <0.001).

After HD sessions (low-flux dialyzer), an average of 2900 mL fluid was removed by ultrafiltration, systolic and diastolic blood pressure decreased by 13 mmHg (P <0.01) and 5 mmHg (P <0.01), respectively, and heart rate increased by 2 bpm (P = 0.03). The peptides reacted differently to a dialysis session. NT-proBNP increased by 14% (from 9509 to 9711 ng/L, P = 0.03), BNP decreased by 17% (from 348 to 271 ng/L, P <0.01), and ANP decreased by 56% (from 174 to 70 ng/L, P <0.01). The correlation between pre- and postdialysis measurements of any peptide was very high (P <0.001, r = 0.94 for NT-proBNP, 0.94 for BNP, and 0.85 for ANP), and the same set of significant variables entered both pre- and post-HD multiple regression equations.


We compared the concentrations of natriuretic peptides in uremic patients with abolished renal function with those in cardiac patients with normal or slightly decreased renal function to establish whether uremic status or cardiomyopathy affects plasma concentrations of the peptides in HD patients. Although patients in the HD and DCM groups belonged to the same NYHA class and both cardiomyopathies were likely characterized by a similar myocyte disarray and intermyocyte fibrosis (17), the groups differed in their extreme values of renal function and Doppler-echocardiographic parameters. Heart involvement was more severe in the DCM patients. If heart function had been the determinant for plasma peptide concentrations, increased concentrations of the peptides should have been found in the DCM group owing to increased wall stress (9). Peptide concentrations instead were increased 5- to 25-fold in the HD patients, indicating that uremic status and not heart involvement was the major determinant of the peptide increase. Peptides were also increased 2- to 4-fold in the DCM patients with early renal dysfunction compared to those with preserved GFR, reflecting the inverse linear relation with GFR. If heart function had been the determinant for plasma peptide concentrations in DCM patients, no difference should have been found in the patients with lower vs higher GFR values because measures of heart involvement were similar in the 2 groups.

Increased concentrations of NT-proBNP, BNP, and ANP have been reported in dialysis patients compared to patients with mild and moderate renal dysfunction (2, 17, 19). We extended the investigation to cardiac patients with preserved renal function. However, the hydration status of both groups, as assessed by bioelectrical impedance vector analysis (20), was normal and comparable.

We suggest 4 explanatory variables that significantly fitted the 3 different natriuretic peptide concentrations in the DCM and HD groups: uremic status, diastolic pattern, left atrial volume, and BMI. Abolished GFR had the greatest influence on the increased peptide concentrations. Although higher peptide concentrations are associated with a worse prognosis, there is agreement in the literature that current decision thresholds for BNP without adjustment for kidney function should not be applied (18, 21-24). Empirical thresholds have been suggested in mild-to-moderate renal dysfunction, e.g., BNP 300 ng/L instead of 100 ng/L for GFR of 18-60 mL/min (22) and 390 ng/L in HD patients (21). We found that even in cardiac patients with normal GFR, the relationship between peptides and GFR was continuous and linear (Fig. 3), therefore preventing the identification of any fixed decision threshold. Peptide concentration expression corrected for GFR is impractical and cannot be used at all in uremic patients with abolished GFR.

Diagnostic testing is useful for identifying a decision threshold with high sensitivity and specificity that should be independent of other clinical conditions. We provide evidence that natriuretic peptide concentrations depend more on GFR than on cardiac involvement, both in the extreme reduction of GFR and in the initial renal dysfunction. The confounding effect of renal dysfunction explains why natriuretic peptides are unable to detect systolic dysfunction. Therefore, although the validity of decision thresholds should probably be restricted to GFR >100 mL * [min.sup.-1] * [(1.73 [m.sup.2]).sup.-1] (Fig. 3), changes in peptide concentrations over time may be meaningful in the same patient with stable renal function. For instance, our equation predicts that a 3.5-fold increase in the NT-proBNP value from 2640 to 9500 ng/L in an HD patient would correspond to the increase from 125 to 450 ng/L in a DCM patient with comparable diastolic pattern, atrial volume, and BMI. Specific outcome studies are needed to test our preliminary hypothesis and to establish whether our equations can be used for a correction procedure in uremic patients in a larger study group.

After an HD session, a variable decrease in circulating peptides has been reported, especially with high-flux dialyzers (2, 3). The effects of our dialysis session with low-flux dialyzers differed among the peptides. We have no clear explanation for the different behaviors of the peptides, which can reflect different half-lives combined with the different molecular sizes. However, the cross-correlation between peptides, the high correlation between pre- and postdialysis measurements of any peptide, and the same set of significant variables in the multiple regression equations indicate that the predialysis ranking of individual values is preserved after dialysis, meaning that long- rather than short-term regulation is stronger.

Several reports support a regulatory role of left ventricular diastolic pattern and left atrial volume on circulating peptide concentrations (5, 8, 25-29). The meaning of the inverse relationship between natriuretic peptide concentration and BMI is not clear in the literature (30-32). In our study, ANP, BNP, and NT-proBNP decreased with the increase of BMI in the 17 to 35 kg/[m.sup.2] range. In the absence of other data, we consider BMI as a scale factor for peptide metabolism in different body compartments.

Other potential explanatory variables reported in the literature, such as blood pressure (33, 34), C-reactive protein (35), ventricular wall thickness and mass (33, 36), and ejection fraction (36), although correlated with peptides, were not able to enter the regression equation with a significant contribution in our study. The strict selection criteria of patients in our protocol rules out confounding factors such as ischemia, pulmonary disorders, diabetes, obesity, abnormal body hydration, or differences in the NYHA class (2, 5-7).

A limitation of the present study is the lack of a follow-up period evaluating the association between peptide concentrations and outcomes in the 2 cardiomyopathies. In addition, we studied only patients in NYHA class I and II without diabetes and ischemic heart disease.

In conclusion, abolished renal function rather than cardiomyopathy was the cause of increased peptides in HD, the long-term regulation of which was stronger than 1 HD session. Natriuretic peptide concentrations were dependent on GFR even at the onset of renal dysfunction.

Grant/funding support: Italian government, Ministry of University and Research, "Ex 60%" fund.

Financial disclosures: None declared.

Received March 30, 2007; accepted September 18, 2007. Previously published online at DOI: 10.1373/clinchem.2007.089656


(1.) Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004;50:33-50.

(2.) Wahl HG, Graf S, Renz H, Fassbinder W. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 2004;50:1071-4.

(3.) Suresh M, Farrington K. Natriuretic peptides and the dialysis patient. Semin Dial 2005;18:409-19.

(4.) Tyralla K, Amann K. Cardiovascular changes in renal failure. Blood Purif 2002;20:462-5.

(5.) Casserly LF, Givertz MM. Congestive heart failure and its management in end-stage renal failure. In: Loscalzo J, London GM, eds. Cardiovascular Disease in End-Stage Renal Failure. New York: Oxford University Press Inc., 2000:289-315.

(6.) Mall G, Huther W, Schneider J, Lundin P, Ritz E. Diffuse intermyocardiocytic fibrosis in uremic patients. Nephrol Dial Transplant 1990;5:39-44.

(7.) McKie PM, Burnett JC Jr. B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clin Proc 2005;80:1029-36.

(8.) Aoki J, Ikari Y, Nakajima H, Mori M, Sugimoto T, Hatori M, et al. Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int 2005;67:333-40.

(9.) Mizuno Y, Yoshimura M, Harada E, Nakayama M, Sakamoto T, Shimasaki Y, et al. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 2000;86:1036-40.

(10.) Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connel J, et al. Report of the 1995 World Health Organization/ International Society and Federation of Cardiology Task Force on the definition and classification of card iomyopathies. Circulation 1996;93:841-2.

(11.) Piccoli A, Nigrelli S, Caberlotto A, Bottazzo S, Rossi B, Pillon L, et al. Bivariate normal values of the bioelectrical impedance vector in adult and elderly populations. Am J Clin Nutr 1995;61:269-70.

(12.) The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000;36:959-69.

(13.) Anderson B. Echocardiography: The Normal Examination and Echocardiographic Measurements. Manly, Queensland: MGA Graphics, 2000.

(14.) Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57: 450-8.

(15.) Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 2000;102:1788-94.

(16.) Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol 1997;30:8-18.

(17.) National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(Suppl 1):S1-266.

(18.) Safley DM, Awad A, Sullivan RA, Sandberg KR, Mourad I, Boulware M, et al. Changes in B-type natriuretic peptide levels in hemodialysis and the effect of depressed left ventricular function. Adv Chronic Kidney Dis 2005;12:117-24.

(19.) Apple FS, Murakami MM, Pearce LA, Herzog CH. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004;50: 2279-85.

(20.) Piccoli A, for the Italian HD-BIA study group. Identification of operational clues to dry weight prescription in hemodialysis using bioimpedance vector analysis. Kidney Int 1998;53:1036-43.

(21.) Goto T, Takase H, Toriyama T, Sugiura T, Kurita Y, Tsuru N, et al. Increased circulating levels of natriuretic peptides predict future cardiac events in patients with chronic hemodialysis. Nephron 2002;92:610-5.

(22.) Mueller C, Laule-Kilian K, Scholer A, Nusbaumer C, Zeller T, Staub D, et al. B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison. Kidney Int 2005;67:278-84.

(23.) McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571-9.

(24.) Mark PB, Stewart GA, Gansevoort RT, Petrie CJ, McDonagh TA, Dargie HJ, et al. Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. Nephrol Dial Transplant 2006;21:402-10.

(25.) Fruhwald FM, Fahrleitner A, Watzinger N, Fruhwald S, Dobnig H, Schumacher M, et al. Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy. Eur Heart J 1999;20:1415-23.

(26.) Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol 2003;92:1434-8.

(27.) Luchner A, Stevens TL, Borgeson DD, Redfield M, Wei CM, Porter JG, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol Heart Circ Physiol 1998;274:H1684-9.

(28.) Atherton JJ, Moore TD, Thomson HL, Frenneaux MP. Restrictive left ventricular filling patterns are predictive of diastolic ventricular interaction in chronic heart failure. J Am Coll Cardiol 1998;31: 413-8.

(29.) Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594-600.

(30.) Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL, et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 2005;149:744-50.

(31.) Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides. Circulation 2005;112: 2163-8.

(32.) Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996;28:22-30.

(33.) Yasumoto K, Takata M, Ueno H, Tomita S, Tomoda F, Inoue H. Relation of plasma brain and atrial natriuretic peptides to left ventricular geometric patterns in essential hypertension. Am J Hypertens 1999;12:921-4.

(34.) Ortega 0, Gallar P, Munoz M, Rodriguez I, Carreno A, Ortiz M, et al. Association between C-reactive protein levels and N-terminal pro-B-type natriuretic peptide in pre-dialysis patients. Nephrol Clin Pract 2004;97:125-30.

(35.) Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001;12:1508-15.

(36.) Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005;46:610-20.

[4] Nonstandard abbreviations: ANP, A-type natriuretic peptide; BNP, B-type natriuretic peptide; NT-proBNP, N-terminal fragment of proBNP; HD, hemodialysis; DCM, dilated cardiomyopathy; GFR, glomerular filtration rate; BMI, body mass index; NYHA, New York Heart Association; CRP, C-reactive protein; Ln, natural logarithmic; N-AR, normal or abnormal relaxation diastolic pattern; Pn-R, pseudonormal or restrictive diastolic pattern; NS, not significant.


Divisions of [1] Nephrology, [2] Laboratory Medicine, and [3] Cardiology, University Hospital, University of Padova, Italy.

* Address correspondence to this author at: Division of Nephrology, University Hospital, University of Padova, Policlinico IV piano, Via Giustiniani, 2, I-35128 Padova, Italy. Fax 39-049 618157; e-mail
Table 1. Demographic and metabolic characteristics of patients by
GFR in the DCM group and by disease group. (a)

 GFR <85
 mL * [min.sup.-1] *
 [(1.73 [m.sup.2]).sup.-1]

Age, years 57.3 (2.7)
BMI, kg/[m.sup.2] 24.2 (0.7)
Systolic blood pressure, mmHg 123.2 (2.7)
Diastolic blood pressure, mmHg 79.4 (1.8)
Mean blood pressure, mmHg 93.9 (1.9)
Urea, mmol/L 6.1 (0.2)
Creatinine, [micro]mol/L 72.0 (2.2)
Hemoglobin, g/L 137.0 (2.3)
C-reactive protein, mg/L 1.2 (1.2)
Resistance/height, Ohm/m 297.9 (12.8)
Reactance/height, Ohm/m 30.3(l.1)
NT-proBNP, ng/L 785 (1.3)
BNP, ng/L 135 (1.3)
ANP, ng/L 56(1.3)

 GFR >85
 mL * [min.sup.-1] *
 [(1.73 [m.sup.2]).sup.-1]

Age, years 49.9 (2.6)
BMI, kg/[m.sup.2] 25.6 (0.8)
Systolic blood pressure, mmHg 133.0 (3.3)
Diastolic blood pressure, mmHg 78.4 (1.9)
Mean blood pressure, mmHg 96.7 (2.2)
Urea, mmol/L 8.6 (0.5)
Creatinine, [micro]mol/L 99.8 (3.2)
Hemoglobin, g/L 138.7 (3.1)
C-reactive protein, mg/L 1.7 (1.2)
Resistance/height, Ohm/m 295.2 (10.9)
Reactance/height, Ohm/m 31.4(l.1)
NT-proBNP, ng/L 191 (1.3)
BNP, ng/L 40(1.3)
ANP, ng/L 23(1.3)


Age, years NS 53.7 (1.9)
BMI, kg/[m.sup.2] NS 24.9 (0.5)
Systolic blood pressure, mmHg 0.03 128.1 (2.2)
Diastolic blood pressure, mmHg NS 78.9 (1.3)
Mean blood pressure, mmHg NS 95.3 (1.4)
Urea, mmol/L <0.001 7.3 (0.3)
Creatinine, [micro]mol/L <0.001 88.9 (2.8)
Hemoglobin, g/L NS 138.9(l.9)
C-reactive protein, mg/L NS 1.4 (1.2)
Resistance/height, Ohm/m NS 296.5 (8.3)
Reactance/height, Ohm/m NS 30.8 (0.8)
NT-proBNP, ng/L 0.001 387 (1.3)
BNP, ng/L 0.004 74(1.2)
ANP, ng/L 0.006 36(1.2)


Age, years 62.8 (2.2) 0.002
BMI, kg/[m.sup.2] 24.8 (0.4) NS
Systolic blood pressure, mmHg 142.4 (3.1) <0.001
Diastolic blood pressure, mmHg 78.3 (1.8) NS
Mean blood pressure, mmHg 99.7 (2.1) NS
Urea, mmol/L 22.3 (0.8) <0.001
Creatinine, [micro]mol/L 796.4 (22.3) <0.001
Hemoglobin, g/L 112.7(l.6) <0.001
C-reactive protein, mg/L 4.8 (1.2) <0.001
Resistance/height, Ohm/m 307.0 (6.9) NS
Reactance/height, Ohm/m 26.8 (0.9) 0.001
NT-proBNP, ng/L 9509 (1.2) <0.001
BNP, ng/L 348 (1.2) <0.001
ANP, ng/L 174 (1.1) <0.001

(a) Data are mean (SE); geometric mean of CRP, NT-proBNP, BNP, and
ANP. The 95% CI of the geometric mean is the antilog of Ln(M)
[+ or -] 2 Ln(SE). SD = 2.24 SE for all variables. Resistance and
Reactance are the bioimpedance vector components.

Table 2. Mean values of Doppler echocardiography variables by GFR
in the DCM group and by disease group. (a)

 GFR <85
 mL * [min.sup.-1] *
 [(1.73 [m.sup.2]).sup.-1]

Posterior wall thickness, mm 11.0 (0.3)
Interventricular wall thickness, mm 10.2 (0.3)
Ventricular diameter, mm 68.1 (2.4)
Relative wall thickness 0.3 (0.01)
End-diastolic volume, mL/[m.sup.2] 123.9 (9.4)
End-systolic volume, mL/[m.sup.2] 82.9 (8.3)
Ejection fraction, % 35.4 (2.2)
Ventricular mass, g/[m.sup.2] 188.3 (11.9)
Left atrial volume, mL/[m.sup.2] 41.1 (3.3)
Peak E wave/peak A wave 1.4 (0.2)
Deceleration time E wave, ms 215.4 (16.2)
Myocardial performance index 0.7 (0.1)
Pulmonary systolic wave, ms 51.1 (3.6)
Pulmonary diastolic wave, ms 47.4 (3.0)
Pulmonary diastolic/systolic 0.9 (0.1)

 GFR >85
 mL * [min.sup.-1] *
 [(1.73 [m.sup.2]).sup.-1]

Posterior wall thickness, mm 10.1 (0.3)
Interventricular wall thickness, mm 9.7 (0.3)
Ventricular diameter, mm 65.2 (2.2)
Relative wall thickness 0.3 (0.01)
End-diastolic volume, mL/[m.sup.2] 98.3 (5.3)
End-systolic volume, mL/[m.sup.2] 60.4 (4.2)
Ejection fraction, % 39.7 (1.3)
Ventricular mass, g/[m.sup.2] 154.8 (9.3)
Left atrial volume, mL/[m.sup.2] 39.1 (2.7)
Peak E wave/peak A wave 1.2 (0.1)
Deceleration time E wave, ms 227.9 (14.6)
Myocardial performance index 0.7 (0.1)
Pulmonary systolic wave, ms 55.3 (4.4)
Pulmonary diastolic wave, ms 48.5 (3.6)
Pulmonary diastolic/systolic 0.9 (0.1)


Posterior wall thickness, mm NS 10.6 (0.2)
Interventricular wall thickness, mm NS 9.9 (0.2)
Ventricular diameter, mm NS 66.6 (1.6)
Relative wall thickness NS 0.3 (0.01)
End-diastolic volume, mL/[m.sup.2] 0.02 111.1 (5.6)
End-systolic volume, mL/[m.sup.2] 0.02 71.6 (4.9)
Ejection fraction, % NS 37.6 (1.3)
Ventricular mass, g/[m.sup.2] 0.03 171.6 (7.9)
Left atrial volume, mL/[m.sup.2] NS 40.1 (2.1)
Peak E wave/peak A wave NS 1.3 (0.1)
Deceleration time E wave, ms NS 221.6 (10.8)
Myocardial performance index NS 0.7 (0.04)
Pulmonary systolic wave, ms NS 52.9 (2.8)
Pulmonary diastolic wave, ms NS 47.9 (2.3)
Pulmonary diastolic/systolic NS 0.9 (0.04)


Posterior wall thickness, mm 13.6 (0.5) <0.001
Interventricular wall thickness, mm 12.5 (0.4) <0.001
Ventricular diameter, mm 50.1 (1.4) <0.001
Relative wall thickness 0.5 (0.03) <0.001
End-diastolic volume, mL/[m.sup.2] 62.4 (2.9) <0.001
End-systolic volume, mL/[m.sup.2] 24.7 (1.6) <0.001
Ejection fraction, % 60.7 (1.2) <0.001
Ventricular mass, g/[m.sup.2] 150.5 (7.3) 0.05
Left atrial volume, mL/[m.sup.2] 54.3 (2.8) <0.001
Peak E wave/peak A wave 1.0 (0.1) 0.03
Deceleration time E wave, ms 173.3 (8.6) 0.01
Myocardial performance index 0.4 (0.02) <0.001
Pulmonary systolic wave, ms 51.7 (2.1) <0.001
Pulmonary diastolic wave, ms 50.7 (1.9) <0.001
Pulmonary diastolic/systolic 1.1 (0.1) NS

(a) Data are mean (SE).
SD can be calculated as 2.24 SE.
COPYRIGHT 2007 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Evidence-Based Laboratory Medicine and Test Utilization
Author:Codognotto, Marta; Piccoli, Antonio; Zaninotto, Martina; Plebani, Mario; Mion, Monica; Vertolli, Ugo
Publication:Clinical Chemistry
Date:Dec 1, 2007
Previous Article:National academy of clinical biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or...
Next Article:Modified form of the fibrinogen B[beta] chain (des-Gln B[beta]), a potential long-lived marker of pancreatitis.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters